文章：

CDK4/6抑制剂在乳腺癌中的最新进展

Recent progress of CDK4/6 inhibitors’ current practice in breast cancer 

原文发布日期：2024-02-26 

英文摘要：

Dysregulated cellular proliferation represents a hallmark feature across all cancers. Aberrant activation of the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway, independent of mitogenic signaling, engenders uncontrolled breast cancer cell proliferation. Consequently, the advent of CDK4/6 inhibition has constituted a pivotal milestone in the realm of targeted breast cancer therapy. The combination of CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) has emerged as the foremost therapeutic modality for patients afflicted with hormone receptor-positive (HR + )/HER2-negative (HER2-) advanced breast cancer. At present, the Food and Drug Administration (FDA) has sanctioned various CDK4/6i for employment as the primary treatment regimen in HR + /HER2- breast cancer. This therapeutic approach has demonstrated a substantial extension of progression-free survival (PFS), often amounting to several months, when administered alongside endocrine therapy. Within this comprehensive review, we systematically evaluate the utilization strategies of CDK4/6i across various subpopulations of breast cancer and explore potential therapeutic avenues following disease progression during application of CDK4/6i therapy. 

摘要翻译：

细胞增殖失调是所有癌症的标志性特征。细胞周期蛋白依赖性激酶4和6（CDK4/6）通路的异常激活——不依赖于有丝分裂信号——导致乳腺癌细胞不受控制地增殖。因此，CDK4/6抑制剂的问世成为靶向乳腺癌治疗领域的关键里程碑。CDK4/6抑制剂（CDK4/6i）与内分泌治疗（ET）联合方案，已成为激素受体阳性（HR+）/HER2阴性（HER2-）晚期乳腺癌患者的一线治疗方案。目前，美国食品药品监督管理局（FDA）已批准多种CDK4/6i作为HR+/HER2-乳腺癌的主要治疗策略。该治疗方案与内分泌治疗联用时，可显著延长无进展生存期（PFS），通常达数月之久。在本篇综述中，我们系统评估了CDK4/6i在乳腺癌不同亚群中的使用策略，并探讨CDK4/6i治疗期间疾病进展后的潜在治疗路径。

原文链接：

Recent progress of CDK4/6 inhibitors’ current practice in breast cancer